Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Medical Genetics

Managing IRD: Treatment Strategies and Building Your Care Team

At a Glance

Managing Infantile Refsum Disease (IRD) requires a multidisciplinary care team to address multisystem symptoms. Key treatments include supervised dietary restriction of phytanic acid, vitamin A, D, E, and K supplementation, cholic acid therapy, and rigorous long-term liver monitoring.

Managing Infantile Refsum Disease (IRD) requires a shift from looking for a single “cure” to building a comprehensive, supportive care plan. Because IRD is a multisystem disorder, its management is primarily focused on treating symptoms, preventing complications, and supporting your child’s unique developmental path [1][2][3].

Building Your Care Team

A coordinated team approach is essential to ensure that a treatment for one symptom doesn’t negatively impact another [1][4]. Your “core” team should include:

  • Metabolic Geneticist: The “quarterback” of your child’s care, who understands the underlying biology of the PEX mutation [1].
  • Genetic Counselor: Vital for helping you understand the inheritance pattern, testing siblings, and navigating family planning [5].
  • Metabolic Dietitian/Nutritionist: Essential for managing dietary needs and preventing malnutrition [6].
  • Hepatologist (Liver Specialist): To monitor liver function and screen for long-term risks [7].
  • Ophthalmologist: To track retinal changes and help maximize remaining vision [8].
  • Audiologist: To manage hearing loss, which may include fitting hearing aids or evaluating for cochlear implants [2].
  • Neurologist: To monitor brain health and manage any potential issues like seizures or muscle tone [2].

Nutrition and Dietary Management

Because children with IRD cannot effectively break down phytanic acid, it builds up to toxic levels [9]. Phytanic acid is found primarily in dairy products and the fats of ruminant animals (like cows and sheep).

  • Dietary Restriction: Restricting phytanic acid in the diet is a standard part of care. However, you must never alter your infant’s or child’s diet without the strict supervision of a metabolic dietitian. Unlike Adult Refsum Disease, diet alone will not stop the progression of IRD, but it is necessary to reduce toxicity [6][10].
  • Vitamin Supplementation: Due to liver and bile acid issues, children with IRD frequently struggle to absorb fat-soluble vitamins. Regular monitoring and supplementation of Vitamins A, D, E, and K are critical [11][12].
  • DHA Oil: Some parents may read about DHA (docosahexaenoic acid) supplementation online. While often discussed, its long-term efficacy is still debated in the medical community. Discuss this directly with your metabolic team before starting any supplements [11].

Long-Term Liver Surveillance

Even if liver function looks “normal” on standard tests, the absence of functional peroxisomes puts the liver under constant stress [7][13].

  • The Risk: Over time, children with ZSD are at a higher risk for fibrosis (scarring), cirrhosis (advanced scarring), and a type of liver cancer called hepatocellular carcinoma (HCC) [7][14].
  • The Monitoring: Standard care includes regular liver ultrasounds and blood tests for alpha-fetoprotein (AFP), which can be an early warning sign of liver tumors [7].
  • The Reality of Liver Transplantation: In rare cases of severe liver disease or pre-cancer, a liver transplant may be considered to stabilize liver health [14][15]. Crucially, parents must understand that a liver transplant is not a cure. While it provides a healthy liver, it does not correct the genetic defect in the brain, eyes, or ears, meaning neurological and sensory symptoms will still progress [16][15].

Targeted and Investigational Treatments

While most care is supportive, there are specific medical interventions and ongoing research you should discuss with your team:

  • Bile Acid Therapy (Cholic Acid/Kolbam): This is an FDA-approved oral medication that helps “turn off” the production of toxic, abnormal bile acids that the liver can’t process [17][18].
  • Small-Molecule Stabilizers: For children with specific mutations (like PEX1-G843D), researchers are testing “chaperone” molecules that help “fix” the shape of the broken protein [19].
  • Gene Therapy & Stem Cells: Pre-clinical research is looking into gene augmentation for the retina, and stem cell transplants are being investigated in very specific cases, though they are not yet a standard treatment for the IRD phenotype [20][4].

Common questions in this guide

How do we manage phytanic acid in a child with Infantile Refsum Disease?
Restricting phytanic acid, which is found in dairy and ruminant animal fats, is standard for reducing toxicity. However, you must only alter your child's diet under the strict supervision of a metabolic dietitian to ensure they receive proper overall nutrition.
Which vitamin supplements do children with IRD need?
Because of liver and bile acid issues, children with IRD often struggle to absorb fat-soluble vitamins. They require regular testing and supplementation of vitamins A, D, E, and K to maintain their health.
Why are regular liver ultrasounds necessary for IRD?
Children with IRD are at a higher risk for liver scarring, cirrhosis, and liver cancer due to constant stress on the organ. Regular ultrasounds and alpha-fetoprotein (AFP) blood tests help doctors monitor liver health and catch any tumors early.
Is a liver transplant a cure for Infantile Refsum Disease?
No, a liver transplant is not a cure. While it can stabilize severe liver disease and provide a healthy liver, it does not correct the underlying genetic defect, meaning neurological and sensory symptoms in the brain, eyes, and ears will continue to progress.
What is cholic acid (Kolbam) therapy used for in IRD?
Cholic acid, also known as Kolbam, is an FDA-approved oral medication. It helps stop the production of toxic, abnormal bile acids that an IRD patient's liver cannot properly process.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How do we safely restrict phytanic acid in my child's diet without compromising their overall nutrition?
  2. 2.Which fat-soluble vitamins (A, D, E, K) should we be supplementing and testing for regularly?
  3. 3.What is our specific schedule for liver ultrasounds and AFP (alpha-fetoprotein) blood tests to screen for tumors?
  4. 4.Is my child a candidate for cholic acid (Kolbam) therapy, and what are the risks if they already have some liver scarring?
  5. 5.Can we schedule a meeting with the genetic counselor to discuss family planning and sibling testing?
  6. 6.How many other patients with Zellweger Spectrum Disorders has this center treated in the last year?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Severe Zellweger spectrum disorder due to a novel missense variant in the PEX13 gene: A case report and the literature review.

    Su L, Peng MZ, Chen XD, et al.

    Molecular genetics & genomic medicine 2024; (12(1)):e2315 doi:10.1002/mgg3.2315.

    PMID: 37962062
  2. 2

    Zellweger spectrum disorders: clinical overview and management approach.

    Klouwer FC, Berendse K, Ferdinandusse S, et al.

    Orphanet journal of rare diseases 2015; (10()):151 doi:10.1186/s13023-015-0368-9.

    PMID: 26627182
  3. 3

    High Dose Versus Low Dose Syngeneic Hepatocyte Transplantation in Pex1-G844D NMRI Mouse Model is Safe but Does Not Achieve Long Term Engraftment.

    Demaret T, Evraerts J, Ravau J, et al.

    Cells 2020; (10(1)) doi:10.3390/cells10010040.

    PMID: 33396635
  4. 4

    Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines.

    Braverman NE, Raymond GV, Rizzo WB, et al.

    Molecular genetics and metabolism 2016; (117(3)):313-21.

    PMID: 26750748
  5. 5

    Genome sequencing identifies a rare case of moderate Zellweger spectrum disorder caused by a PEX3 defect: Case report and literature review.

    Lee W, Costain G, Blaser S, et al.

    Molecular genetics and metabolism reports 2020; (25()):100664 doi:10.1016/j.ymgmr.2020.100664.

    PMID: 33101983
  6. 6

    Comparison of Caregiver-Reported Dietary Intake Methods in Zellweger Spectrum Disorder.

    Bose M, von Thun NL, Kerrihard AL, et al.

    Nutrients 2025; (17(6)) doi:10.3390/nu17060989.

    PMID: 40290032
  7. 7

    Hepatic symptoms and histology in 13 patients with a Zellweger spectrum disorder.

    Berendse K, Koot BGP, Klouwer FCC, et al.

    Journal of inherited metabolic disease 2019; (42(5)):955-965 doi:10.1002/jimd.12132.

    PMID: 31150129
  8. 8

    Systematic study of ophthalmological findings in 10 patients with PEX1-mediated Zellweger spectrum disorder.

    Karuntu JS, Klouwer FCC, Engelen M, Boon CJF

    Ophthalmic genetics 2024; (45(4)):351-362 doi:10.1080/13816810.2024.2330389.

    PMID: 38664000
  9. 9

    Comparison of the Diagnostic Performance of C26:0-Lysophosphatidylcholine and Very Long-Chain Fatty Acids Analysis for Peroxisomal Disorders.

    Jaspers YRJ, Ferdinandusse S, Dijkstra IME, et al.

    Frontiers in cell and developmental biology 2020; (8()):690 doi:10.3389/fcell.2020.00690.

    PMID: 32903870
  10. 10

    Application of machine learning algorithms for the differential diagnosis of peroxisomal disorders.

    Subhashini P, Jaya Krishna S, Usha Rani G, et al.

    Journal of biochemistry 2019; (165(1)):67-73 doi:10.1093/jb/mvy085.

    PMID: 30295825
  11. 11

    A Retrospective Study of Hearing Loss in Patients Diagnosed with Peroxisome Biogenesis Disorders in the Zellweger Spectrum.

    Lee J, Yergeau C, Kawai K, et al.

    Ear and hearing 2022; (43(2)):582-591 doi:10.1097/AUD.0000000000001126.

    PMID: 34534157
  12. 12

    Zellweger spectrum disorder: A cross-sectional study of symptom prevalence using input from family caregivers.

    Bose M, Cuthbertson DD, Fraser MA, et al.

    Molecular genetics and metabolism reports 2020; (25()):100694 doi:10.1016/j.ymgmr.2020.100694.

    PMID: 33335840
  13. 13

    Treatment of Inborn Errors by Product Replacement: The Example of Inborn Errors of Bile Acid Synthesis.

    Clayton PT, Hirachan R, Murphy E

    Journal of inherited metabolic disease 2025; (48(5)):e70081 doi:10.1002/jimd.70081.

    PMID: 40847535
  14. 14

    Liver Transplantation for Zellweger Syndrome.

    Menon J, Shanmugam N, Vij M, et al.

    Indian journal of pediatrics 2024; (91(5)):507-509 doi:10.1007/s12098-023-04937-7.

    PMID: 38117438
  15. 15

    Successful Treatment of Severe Hepatopulmonary Syndrome as a Rare Complication of Zellweger Spectrum Disorder.

    Tharakan RM, Rajwal S, Schwahn BC

    JIMD reports 2025; (66(5)):e70026 doi:10.1002/jmd2.70026.

    PMID: 40895213
  16. 16

    Living-Donor Liver Transplantation From a Heterozygous Parent for Infantile Refsum Disease.

    Matsunami M, Shimozawa N, Fukuda A, et al.

    Pediatrics 2016; (137(6)).

    PMID: 27221287
  17. 17

    The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapy.

    Klouwer FCC, Koot BGP, Berendse K, et al.

    Journal of inherited metabolic disease 2019; (42(2)):303-312 doi:10.1002/jimd.12042.

    PMID: 30793331
  18. 18

    Long-Term Cholic Acid Treatment in a Patient with Zellweger Spectrum Disorder.

    Heubi JE, Bishop WP

    Case reports in gastroenterology 2018; (12(3)):661-670 doi:10.1159/000494555.

    PMID: 30519152
  19. 19

    PEX1G843D remains functional in peroxisome biogenesis but is rapidly degraded by the proteasome.

    Sheedy CJ, Chowdhury SP, Ali BA, et al.

    The Journal of biological chemistry 2025; (301(5)):108467 doi:10.1016/j.jbc.2025.108467.

    PMID: 40158855
  20. 20

    AAV-mediated PEX1 gene augmentation improves visual function in the PEX1-Gly844Asp mouse model for mild Zellweger spectrum disorder.

    Argyriou C, Polosa A, Song JY, et al.

    Molecular therapy. Methods & clinical development 2021; (23()):225-240 doi:10.1016/j.omtm.2021.09.002.

    PMID: 34703844

This page provides educational information on managing Infantile Refsum Disease. Always consult your child's metabolic geneticist and specialized care team before altering diets or starting new treatments.

Get notified when new evidence is published on Infantile Refsum disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.